ATC Group: J02AC02 Itraconazole

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J02AC02 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J02 Antimycotics for systemic use
3 J02A Antimycotics for systemic use
4 J02AC Triazole and tetrazole derivatives
5 J02AC02 Itraconazole

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.2 g
PAREN - Parenteral 0.2 g

Active ingredients in J02AC02

Active Ingredient Description
Itraconazole

Itraconazole is a triazole derivative that inhibits fungal 14α-demethylase, resulting in a depletion of ergosterol and disruption of membrane synthesis by fungi.

Related product monographs

Title Information Source Document Type  
SPORANOX I.V. Concentrate and solvent for solution for infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Canada (CA)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Germany (DE)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Malta (MT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Nigeria (NG)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.